NCT01520103 - Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Her2-negative Metastatic Breast CancerHer2-negative Locally Advanced Breast Cancer

Interventions

DRUG

Vinorebine, Everolimus

Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress

DRUG

Vinorelbine

Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress

Trial Locations (1)

Hämatologisch-onkologische Gemeinschaftspraxis, Münster, Münster